Pfizer’s Apixaban gets nod from KFDA

Published: 2011-12-19 06:56:00

Updated: 2011-12-19 06:56:00

Pfizer Korea said that the Korea Food and Drug Administration have approved its Eliquis (apixaban), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Pfizer Inc. co-developed the drug with Bristol-Myers Squibb, which will share...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK